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Abstract. Due to the high toxicity and side effects of the 
use of traditional chemotherapy in cancer, scientists are 
working on the development of alternative therapeutic tech-
nologies. An example of this is the use of death-induced gene 
therapy. This therapy consists of the killing of tumor cells 
via transfection with plasmid DNA (pDNA) that contains a 
gene which produces a protein that results in the apoptosis 
of cancerous cells. The cell death is caused by the direct 
activation of apoptosis (apoptosis-induced gene therapy) or 
by the protein toxic effects (toxin-induced gene therapy). The 
introduction of pDNA into the tumor cells has been a chal-
lenge for the development of this therapy. The most recent 
implementation of gene vectors is the use of polymeric or 
inorganic nanoparticles, which have biological and physi-
cochemical properties (shape, size, surface charge, water 
interaction and biodegradation rate) that allow them to carry 
the pDNA into the tumor cell. Furthermore, nanoparticles 
may be functionalized with specific molecules for the recog-
nition of molecular markers on the surface of tumor cells. 
The binding between the nanoparticle and the tumor cell 
induces specific endocytosis, avoiding toxicity in healthy 
cells. Currently, there are no clinical protocols approved 
for the use of nanoparticles in death-induced gene therapy. 
There are still various challenges in the design of the perfect 
transfection vector, however nanoparticles have been demon-
strated to be a suitable candidate. This review describes the 
role of nanoparticles used for pDNA transfection and key 
aspects for their use in death-induced gene therapy.
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1. Introduction
According to GLOBOCAN, cancer is the first cause of 
mortality worldwide, accounting for 14.1 million new cancer 
cases reported in 2012, and 8.2 million of deaths induced by 
cancer. One of the leading causes of the high cancer mortality 
is the limitation of actual treatments based on drugs and 
radiation. These limitations include lack of specificity, reduced 
drug bioavailability, drug rapid blood clearance, poor drug 
solubility, patient resistance and disease relapse. The most effi-
cient treatment for cancer is the use of chemotherapeutics (1). 
These substances, like cisplatin or taxol, have been preferred 
from other therapies because they have a superior efficiency 
of killing cancer cells preferentially by inhibiting replication 
or inducing apoptosis (1,2). Chemotherapeutics with anthra-
cyclines and cyclophosphamide causes serious side effects in 
patients killing healthy cells (3) and tissues like bone marrow, 
epithelial cells, and hair follicles (4). Hence, there seems to 
be an urgent need for developing more efficient treatments 
that may offer fewer side-effects in comparison to the actual 
therapies (5). New technologies for cancer treatment have 
been developed in the recent years based on the research and 
application of nanotechnology and molecular biology (1,2).
Nanotechnology can be defined as the design, fabrica-
tion, and use of nanoparticles, which are structures generally 
from 10 to 100 nm. At least one of its dimensions must be in 
the nanometer scale in order to be considered a nanomaterial. 
Thus, nanomaterials may be formed from a few hundred to 
millions of atoms. Because of their small size, the properties 
of nanoparticles vary from their bulk form. This has been 
linked to various effects such as the high percentage of atoms 
on the surface, high surface free energy of nanomaterials, 
spatial confinement and fewer imperfections in their structure. 
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Different chemical, physical and biological characteristics, 
unique in nanoparticles, can be controlled during their synthesis 
to be used in biomedical applications. These physicochemical 
properties such as size, shape, surface charge, hydrophilic 
interactions, magnetism, and electrical characteristics as well 
as the lack of ability to produce an undesirable immunological 
reaction, make nanoparticles a promising tool in medicine (6). 
A special condition that makes nanotechnology so attractive 
for medicine is the capacity to target the therapy directly to the 
cancerous tissue without affecting healthy tissues, avoiding 
side effects. This characteristic can be possible because 
some cancer cells, such as those from breast, ovary, prostate, 
pancreas, lung and liver express exclusively, or over-express 
on the surface some protein receptors (like growth factor 
receptors or hormone receptors) which can be identified by 
individual elements added to the nanoparticles (4). In cancer 
therapy, the research of nanoparticles for killing cancer cells 
includes a variety of applications such as drug delivery (1), 
photodynamic therapy (5), protein delivery (7) and hyper-
thermia (8). A recent application of nanoparticles in cancer 
treatment is their improvement in gene therapy as a non-viral 
vector, loading nucleic acids in their surface and taking it 
directly inside the target cell nucleus (9).
The development of molecular biology allows the applica-
tion of nucleic acid manipulation techniques in the treatment 
of several genetic diseases like cancer. Gene therapy consists 
in the transfer of genetic material into a target cell nucleus 
for therapeutic issues with relatively minimal side effects. 
This genetic material could be DNA or RNA, the complete 
gene sequence, gene segments or an oligonucleotide. Based 
on the different cancer gene therapy objectives, there are 
two main classifications: Corrective cancer gene therapy or 
death-induced gene therapy. Corrective cancer gene therapy 
deactivates oncogenes or activates non-functioning tumor 
suppressor genes, restoring the normal cellular functions. 
Death-induced gene therapy does not aim for turning cancer 
cells into healthy cells, instead it aims for the complete death 
of the cancerous tissues by the activation of different cellular 
pathways (9).
2. Death‑induced gene therapy
The objective of this kind of treatment is to produce the death 
of cancerous cells by the expression of genes whose protein 
product activates different death pathways. These genes usually 
are administrated in pDNA (9). Plasmids are double-stranded 
circular DNA molecules, and they can be replicated and tran-
scribed once inside the target nucleus cell (10). The commercial 
plasmid used in this application needs to have in their sequence 
an eukaryotic transcription promoter, such as CMV, SV40, 
AFPS or AFPL, to be able to work in mammal cells. With the 
use of modifier enzymes of DNA, such as restriction enzymes 
and ligases, the sequence of the death-inducing gene can be 
added to the commercial plasmid. For monitoring the expres-
sion of the recombinant plasmid, a reporter gene sequence can 
be inserted into the plasmid. The protein products of reporter 
genes, like green fluorescent protein (GFP) or luciferase, can 
be easily quantified by a colorimetric method (11‑13). There 
are several advantages of using pDNA vs. the protein itself; the 
purification of pDNA is less expensive and time‑consuming 
even at large scale, plasmid does not trigger an immune 
response, and tumor cells do not develop resistance to the 
pDNA. There are three principal ways to induce cell death 
in gene therapy: a) apoptosis-induced, b) toxin-induced and 
c) gene-directed enzyme prodrug therapy (GDEPT) (4).
a) Apoptosis‑induced cancer therapy. A strategy in 
death-induced gene therapy is the expression of apoptotic genes. 
Genes expressed by cancer cells without affecting healthy tissues 
are preferred (4). Examples of these genes are H19 (encodes 
a long non-coding tumor suppressor RNA), CEA (encodes 
a cell surface glycoprotein which regulates differentiation, 
apoptosis, and cell polarity), and UPAR (encodes the receptor 
for urokinase plasminogen activator, activating the degradation 
of the extracellular matrix) (14). Another important commonly 
studied gene is TRAIL, which encodes a cytokine that belongs 
to the tumor necrosis factor (TNF) ligand family. This protein 
induces apoptosis preferentially in cancer cells (14-15). Other 
genes members of the TNF-receptor family expressed in 
normal apoptosis process are FAS (encodes induced cellular 
death), FASL (encodes a membrane protein for the induction of 
apoptosis), and BCL2 (encodes a membrane receptor for tumor 
necrosis factor α) (14,16).
b) Toxin‑induced gene therapy. Toxins are chemical 
substances that interact with the cells at molecular levels, 
with biological macromolecules such as enzymes and cellular 
receptors, causing toxic effects. These toxins are found in 
some microbes, plants, and animals as part of their defensive 
or predation strategies. Different toxins have been proposed for 
biomedical applications in Toxin-induced gene therapy (17). 
Examples of bacterial toxins studied for cancer treatment are 
diphtheria toxin (DT) from Corynebacterium diphtheria, 
whose toxin inhibits the protein synthesis by inactivating 
eukaryotic elongation factor-2 (EF-2); exotoxin A (ETA) from 
Pseudomonas aeruginosa which inhibits the protein synthesis 
by the inhibition of EF-2 as well; streptolysin O (SLO) from 
Streptococcus which binds to membrane cholesterol and oligo-
merizes making a large pore; and membrane protein product of 
gef gene from Escherichia coli which induces arrest of cellular 
respiration. An example of an animal toxin that can be used in 
gene therapy against cancer is the melittin (Mel), an apoptosis 
inducer from bee poison (18). Some plant toxin genes can be 
utilized for cancer treatment too. The most common are the 
ribosome-inactivating proteins (RIPs) which have a rRNA 
N-glycosidase activity. They cleave the bond between adenine 
and ribose (depurination) in the 28S rRNA, blocking the 
recruitment of translation elongation factors and the protein 
synthesis (19). Some examples of RIPs are ricin from the seeds 
of Ricinus communis, saporin from Saponaria officinalis, and 
lunasin from Glycine max seeds (20).
c) GDEPT. It consists of the administration of an 
enzyme-coding gene in combination with a prodrug. The 
enzyme is a non-toxic protein, but their binding with the 
prodrug turns the complex into a toxic compound (21). An 
example of the most common GDEPT system is the TK/GCV 
suicide system. This system is constituted of two elements: 
the transfection with the gene that codifies the enzyme herpes 
simplex virus thymidine kinase (HSV-Tk) and the prodrug 
MOLECULAR MEDICINE REPORTS  17:  1413-1420,  2018 1415
ganciclovir (GCV). The enzyme HSV-Tk is a non-toxic 
product, but once the GCV interacts with the HSV-Tk, it 
turns into ganciclovir triphosphate (GCV-3P). GCV-3P is a 
toxic compound which inhibits DNA polymerase causing 
death (22). Other systems are: cytosine deaminase/5‑fluo-
rocytosine system, which inhibits thymidylate synthase; 
nitroreductase/CB1954 system, which triggers an extensive 
DNA damage; and carboxypeptidase G2/nitrogen mustard 
system, which links with DNA (23).
3. Vectors for DNA transfection
The transfection with the selected gene can be possible 
transferring naked pDNA into target cells, but there are some 
disadvantages of this method. First, the pDNA exhibits a short 
half-life time in blood circulation because of the degradation 
caused by circulating and intracellular nucleases. The rapid 
clearance makes it unavailable for intravenous application in 
the clinic (24). Another pDNA property is the high negative 
charge, same as the cell membrane, decreasing the transfec-
tion effectiveness by simple passive diffusion because of the 
repellency of the electric charges. These disadvantages can be 
improved by the use of a vector. A vector is a structure that 
works as a vehicle, carrying DNA through blood circulation, 
distributing it until it is endocytosed by a cell. There are two 
main types of vectors: viral vectors and non-viral vectors as 
shown in Fig. 1 (25). Principles of action of non-viral vectors 
can be classified into physical and chemical mechanisms (26).
The structure of a virus consists of a genome surrounded 
by a protein coat. For viral  replication, the virus needs 
to insert its genetic material into a host cell to use the host 
replication and transcription machine. A virus can be 
genetically modified in order to make it harmless, changing 
their infectious genome for the therapeutic genetic material. 
Because of their transfection efficiency viral vectors are the 
most commonly studied vectors for gene therapy. Viruses that 
can be modified for their use in gene therapy are adenovirus, 
herpes simplex virus, vaccinia virus, retrovirus, lentivirus, 
adeno-associated virus, and reovirus. The transfection 
efficiency of viruses is superior from other methods, but there 
are several disadvantages like immune recognition for most of 
the viruses, mutagenic interaction of retrovirus and lentivirus, 
and inflammatory toxicity of adenovirus (22,27).
An alternative from the use of potentially dangerous viral 
vectors are those based on physical or chemical mechanisms. 
Vectors based on physical methods such as hydrodynamic 
methods, gene gun, and electroporation have good results 
ex vivo, but in vivo protocols need to be developed to increase 
their transfection efficiency, avoiding risk for the patient (22). 
Nanoparticles are vectors based on chemical principles and 
they have several properties that make them a promising 
vector for pDNA transfection. An essential characteristic 
that makes nanoparticles available for gene transfection is a 
cationic surface charge. pDNA have a high negative charge, so 
nanoparticles must have positive surface charges to generate 
electrostatic interactions with pDNA. pDNA and cationic 
nanoparticles interact by simple contact, and the pDNA is 
loaded on the surface of the nanoparticles creating a complex. 
This complex is easily taken inside the cell in comparison to 
naked pDNA because the cellular membrane is negatively 
charged and there is no electrostatic repulsion. Another 
characteristic of pDNA bound to nanoparticles is the protec-
tion against degradation by blood nucleases, improving the 
bioavailability of the therapeutic agent (28,29).
4. Nanoparticles for pDNA transfection
Even when there is a background about the use of nanopar-
ticles in the clinic, there are no clinical protocols approved for 
death-induced gene therapy. Since 1995, the Food and Drug 
Administration (FDA) has approved the use of some nanopar-
ticles by oral, local, topical and systemic administration for 
cancer treatment. These are structures that carry a chemo-
therapeutic agent all over the patient's body (30). Despite the 
lack of clinical studies of nanoparticles carrying nucleic acids 
Figure 1. Viral (A) and non-viral (B and C) vectors commonly used for 
therapy and their principal components are described. (A) Viral vector. It has 
excellent transfection efficiency, but triggers an antiviral immune response. 
(B) Liposome. It has an excellent in vitro transfection efficiency, but in vivo 
is an inefficient system because the high surface charges, and (C) poly-
meric nanoparticle. It is stable, sterilizable, with scale-up reproducibility, 
the biodegradation is controllable, it has unique physical properties, low 
immunigenicity, and it is non-toxic; but it has low biocompatibility in some 
inorganic components, the cost of production is expensive, and obtaining of 
recognition molecules is difficult. ScFv, single‑stranded variable fragment; 
NP, nanoparticle.
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as therapeutic agents, there are several pieces of evidence 
of the preclinical efficiency of these nanosystems in gene 
therapy (31-34). Companies have a commercial interest in the 
production of nanoparticles, because of their easy large-scale 
production. The most efficient techniques for scale‑up produc-
tion of pharmaceutical grade nanoparticles are emulsification 
solvent diffusion and nanoprecipitation. These techniques 
allow the formation of particles with a uniform and controlled 
size (35).
Nanoparticles used as nucleic acid carriers include lipo-
somes, inorganic nanoparticles, and polymeric nanoparticles. 
Liposomes are self-assembled vesicles formed by lipid bilayer 
membranes of amphiphilic phospholipids. Liposomes have an 
excellent in vitro transfection capacity; however, they have some 
deficiencies in vivo, due to their high positive charge, which 
induces hemotoxicity, caused by the aggregates produced due 
to the interaction between liposomes and blood proteins. Also, 
these aggregates promote a low transfection rate. Other prob-
lems with liposomes are low stability, industrial production, and 
difficulties in sterilization. In contrast, polymeric and inorganic 
nanoparticles can be easily modified to reduce the excesses 
of positive charges; they are more stable, more reproducible 
and easily sterilizable (36,37). For this reason, polymeric and 
inorganic nanoparticles are considered by several authors as 
promising vectors for gene transfection (38,39).
Currently, biodegradable cationic polymer nanoparticles 
are the most studied. These systems are submicron-sized 
colloidal particles. The properties of the nanoparticles depend 
on their composition, solubility, crystallinity, molecular 
weight, backbone stability, hydrophobicity and polydispersity 
of the selected polymer. It is critical that the polymers selected 
for the preparation of nanoparticles are biocompatible and 
biodegradable. The advantage of using biodegradable poly-
mers is its controlled degradation. This degradation releases 
the plasmid into the cellular cytoplasm once the nanosystem 
is inside the cell. Polymeric nanoparticles also protect nucleic 
acids from nuclease degradation. The cationic property allows 
the binding of the nucleic acid into the nanoparticle surface. 
Natural and synthetic polymers can be used for gene trans-
fection (40,41). Some examples of natural polymers used in 
gene therapy are polysaccharides such as chitosan (41,42) and 
alginate (43), or proteins like albumin (44). Also, synthetic poly-
mers can be employed, such as polycaprolactone (PLC) (45), 
polylactic acid (PLA) (46), polyethyleneimine (PEI) (47), 
poly (lactic-co-glycolic acid) (PLGA) (46,48) or polyethylene 
glycol (PEG) (49).
Inorganic nanoparticles can be easily manipulated in size, 
shape, composition and chemical properties. They are easy to 
prepare in large-scale, easily functionalized and have a high 
degree of transfection. They have various physical properties 
such as electrical, magnetic and optical properties, which 
can be modified during synthesis. These properties can be 
manipulated to obtain optimal conditions to improve transfec-
tion efficiency (35). Examples of this type of nanoparticles are 
carbon nanotubes (50), calcium phosphate nanoparticles (51), 
gold (13), silica (52), and magnetic nanoparticles (53). For 
the use of magnetic nanoparticles such as magnetite, once 
the nanosystem is inside the patient's circulatory system, an 
external electromagnetic field can be applied. In gene therapy, 
the process of directing nucleic acids with the support of 
external magnetic fields is known as magnetofection. The 
efficiency of transfection increases at the moment of applying 
an external electromagnetic field, because it accelerates the 
absorption on the cellular surface (54).
5. Properties of nanoparticles
Because the nanosystem is a foreign body to the organism, 
it must be designed with some unique properties to avoid 
immediate recognition of the immune system, and be quickly 
eliminated from circulation. The first molecular event required 
to discard the nanosystem from circulation is opsonization, 
which is the binding of serum proteins to the surface of the 
nanosystem. This binding is produced by the physicochemical 
proprieties of the nanoparticles, such as the electrostatic charge 
on the nanoparticle surface. Once the nanoparticle is coated by 
these proteins, including complement proteins and immuno-
globulins, the immune system can recognize the complex and 
eliminate it from circulation. That is why specific properties 
are required to avoid the elimination of the nanosystem from 
the body and to ensure its internationalization into the cell. We 
describe these proprieties briefly (55).
i) Shape. Spherical shapes are preferred from sharp corners. 
Some nanoparticles like nanocubes tend to damage smaller 
blood vessels and capillaries (55).
ii) Size. The usual scale of spherical structures is from 30 
to 150 nm. Nanoscale size is required for the system to cross 
biological barriers, like epithelia. Nanoparticles smaller than 
150 nm are capable of performing this action. These dimen-
sions are also optimal to be endocyted by the target cells. 
However, if the size is lower than 30 nm, the nanoparticles 
are immediately discarded by the kidneys and liver from 
the circulatory system. At dimensions bigger than 30 nm 
the nanoparticles cannot pass the glomerular filtration, so 
they remain in the blood. At the range of 30 to 150 nm, the 
blood circulation time is relative to the size; smaller size 
has a longer circulation time, while the larger particles are 
more easily recognized by the macrophages of the immune 
system (56,57).
iii) Surface electrostatic charge. Nanoparticle surface charge 
has to be positive to interact with negative charges over the 
surface of cell membranes. The Z potential of the nanoparticles 
(a measure used to characterize surface charges) must be 
around +25 mV to have stable nanoparticles. Nanoparticles 
in this range of Z potential do not form aggregates due to 
the electrostatic repulsion generated between nanoparticles. 
Nanoparticles with a very low Z potential tends to form 
aggregates because of the lack of electrostatic repulsion 
interactions. Nanoparticles with a very high Z potential can 
cause problems of hemocompatibility due to the interaction 
between nanoparticles and cellular components of the blood, 
causing hemolysis and platelet aggregation (55,57).
iv) Water interactions. If the nanoparticles present hydrophi-
licity, the chemical interactions between nanoparticles and 
water delay the process of opsonization, generating a longer 
lifetime of the nanoparticles in blood. The immune system 
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rapidly discards nanoparticles with hydrophobic properties 
due to its faster opsonization (55).
v) Biodegradability. Biodegradable materials are required 
because the presence of the nanoparticle in the body must not 
be permanent. Biodegradable materials are eliminated once 
the therapeutic action is completed, through normal excretion 
pathways, or they can be integrated into the normal metabolic 
pathways of the cell (55,56). Biodegradability is related to 
the microstructure and composition and its interaction with 
the external physiological environment. Examples of these 
materials include polymers, ceramics and composites (56).
vi) Pegylation. Nanoparticles must have a positive charge to 
immobilize the nucleic acids over their surface, but a high 
positive charge also generates hemocompatibility problems. A 
strategy widely used to eliminate the excess of positive charges 
is the functionalization with PEG. PEG is a polymer with 
no electrostatic charge. PEG regulates the excess of positive 
charges in a nanosystem. Many authors who develop nanopar-
ticles with different medical applications prefer the use of PEG 
to improve their physicochemical proprieties (58-61).
6. Targeting the nanoparticles
One of the key points to improve death-induced gene therapy 
in the clinic is to avoid the expression of suicide genes in 
healthy tissues. The greatest challenge of intelligent treatments 
is to selectively release the therapeutic agent in cancerous 
tissues; several methods are currently under investigation. In 
diseases such as cancer, tumor cells usually express certain 
exclusive receptor proteins, or they can overexpress those 
commonly found in healthy tissues (4). Examples of these 
proteins are human epidermal growth factor receptor-2 
in HER2+ breast cancers (62); mesothelin, urokinase 
plasminogen activator receptor, and some growth factor recep-
tors in pancreatic cancer (63); the α isoform of folate receptor 
in ovarian cancer (64); scavenger receptor type B-1 in chronic 
lymphocytic leukemia (65); folate receptor in acute myeloid 
leukemia (66); prostate-specific membrane antigen (67) 
and matrix metalloproteinase-2 in prostate cancer (68,69). 
These membrane proteins have become targets for specific 
recognition, easily identified by recognition molecules such 
as antibodies, aptamers, proteins and peptides (70). Passive 
non-selective endocytosis of nanoparticles is possible 
because of hydrophobic and electrostatic interactions. To 
improve active endocytosis, nanoparticle surface must be 
modified specifically with recognition molecules (55), immo-
bilized on the surface of the nanoparticles by methods like 
glutaraldehyde (71) or carbodiimide (72).
The most used recognition molecules are monoclonal anti-
bodies (mAbs). Antibodies are proteins (~150 kDa) produced 
by the immune system that have extremely high specificity 
and affinity for their targeted analytes. The use of antibodies 
has an advantage over the use of peptides and aptamers 
because of the low immunogenicity. There is preclinical 
evidence of their efficiency for recognition of targeted cells 
in cancer therapies. However, its size is too big; thus, when 
nanoparticles are functionalized with antibodies, the nano-
system increases its size considerably. A large size hinders the 
intracellular penetration of the nanosystems into solid tumors. 
Another disadvantage is the increase of immunogenicity of 
the system. Finally, there is an extensive need of optimization 
for scale-up manufacturing (73-75). An alternative to this is 
the use of single-stranded variable fragments (scFv). The anti-
body contains two Fab fragments which also have a similar 
specificity compared to complete protein. scFv are 27 kDa 
molecular weight fragments from the fusion of two chains 
from the variable regions of the heavy chain (VH) and the 
light chain (VL) of the antibody, joined by a peptide of 10 to 
Figure 2. Nanosystem construction for death induced gene therapy. (A) The death inductor gene is obtained by PCR and assembled in a commercial mamma-
lian expression plasmid by restriction enzyme technology. (B) Obtaining of ScFv can be possible by the insertion of the DNA sequence into a plasmid. Proteins 
can be expressed in bacteria and then purified. For the evaluation of specificity ELISA test is needed. (C) Nanoparticles are synthesized by chemical methods 
and characterized. Plasmid (by electrostatic interactions) and ScFv (by glutaraldehyde or carbodiimide), are immovilized over the nanoparticle to construct 
the nanosystem. scFv, single-stranded variable fragments.
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25 aminoacids. There are in vivo studies where nanoparticles 
functionalized with scFv against HER2 in breast cancer can 
decrease tumor size. A disadvantage of the use of MAbs and 
scFv is the high cost they generate, so large scale production 
strategies are still a challenge (75-78). Fig. 2 shows the prepa-
ration and construction of a nanosystem for death-induced 
gene therapy using scFv along with recombinant plasmid (71).
Active endocytosis in death-induced gene therapy begins 
in the first instance by administration of the nanosystem, 
usually intravenously. The nanosystem should recirculate 
through the circulatory blood system, avoiding natural 
elimination mechanisms of the host, such as opsonization and 
subsequent phagocytosis by macrophages. The nanosystem 
has the physicochemical properties to interact and cross the 
epithelium (55-56). When the cancer tissue is located, recog-
nition molecules generate a specific binding to the protein 
receptors attached on the surface of cancer cells. This binding 
is called ligand. The ligand activates different molecular 
pathways conducing to endocytosis. Ligand-mediated endo-
cytosis increases the affinity and specificity of the nanosystem 
endocytosis (Fig. 3) (4). The nanosystem is internalized in the 
cell into a vesicle generated by the cell membrane. The vesicle 
enters into the endosomal cellular system where it is degraded. 
The nanosystem is released into the cytoplasm where it begins 
to degrade and it releases all its components into the medium. 
Nanosystem residues are removed from the cell by standard 
excretion mechanisms, or they are incorporated into cellular 
metabolic pathways depending on their nature (4,55). The 
recombinant plasmid, which is the active substance, enters 
into the nucleus through the nuclear pores. Once inside, it is 
recognized by the transcription system, generating the mRNA 
of the death-induced gene. This mRNA goes from the nucleus 
to the cytoplasm, and it is translated into protein. These 
proteins trigger different cellular pathways ending in cellular 
death (20).
7. Conclusion
The use of nanotechnology in medicine promises to be a 
valuable tool in the clinic in the future, both in diagnosis 
and treatment. It promises to reduce the aggressiveness, the 
number of cases, and the mortality of diseases like cancer. 
There are some nanoparticles already approved in the clinic 
by international organizations, but all of them work as a 
vehicle of a drug. There are other promising applications of 
nanoparticles such as hyperthermia or photodynamic therapy. 
In this review, we showed a less known promising application 
of nanoparticles in medicine: as a vector for death induction 
by gene therapy. Because of their chemical, physical and 
biological properties, nanoparticles are superior as a nucleic 
acid carrier than viruses or other physical transfection methods. 
Death-induced gene therapy bet on the total elimination of 
cancerous cells, so the challenge of this therapy is to produce 
the death only in cancerous tissues and not in the healthy ones. 
Despite this, preclinical in vitro and in vivo evidence shows 
that there is possible to transfect cancer cells exclusively 
with the death-induced gene. This kind of genes produces 
different types of proteins which interact with cancerous cells, 
triggering the process of apoptosis. Toxic proteins cannot be 
administrated directly to the patient because the body readily 
Figure 3. Mechanism of the death-induced gene therapy. (a) The scFv on the surface of the nanosystem binds with the cancer biomarker onto the cell 
membrane. (b) Ligand-mediated endocytosis takes place inside a vesicle. (c) Biodegradation occurs, mediated by the endosomal cellular system, releasing 
all the nanosystem components in the cytoplasm. (d) All the non-DNA elements of the nanosystem are eliminated from the cell or integrated into the natural 
cellular metabolism. Recombinant plasmid enters the nucleus by nuclear pores. (e) Once the plasmid DNA is located inside the nucleus, DNA is transcribed 
into mRNA. (f) This mRNA goes to the cytoplasm. (g) The ribosomes traduced it into a protein. (h) Protein induces cell death by different cellular pathways. 
scFv, single-stranded variable fragment.
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degrades proteins. Nanoparticles systems with pDNA are more 
stable than proteins, are easily constructed and easily modified 
to obtain the necessary properties for their use in a patient.
There are still many challenges in the building of the trans-
fection vector with the perfect properties of size, surface charge, 
shape, biodegradation rate, biocompatibility, stability, scale-up 
construction, easiness of sterilization, avoidance of opsoniza-
tion, biodistribution, and specificity. Thanks to their versatility, 
nanoparticles have demonstrated to be a suitable candidate as a 
pDNA carrier. Perfecting the design of different nanoparticles, 
recognition-molecules and death-inductor genes could lead 
death-induced gene therapy systems into the clinical application.
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